IAVI Vaccine Design & Development Laboratory | CPT PPP Coverage
Cryptopolytech (CPT) Public Press Pass (PPP)
News of the Day COVERAGE
200000048 – World Newser
•| #World |•| #Online |•| #Media |•| #Outlet |
View more Headlines & Breaking News here, as covered by cryptopolytech.com
IAVI Vaccine Design & Development Laboratory appeared on www.iavi.org by IAVI.
We’re global leaders in vaccine design for priority pathogens
The IAVI Vaccine Design & Development Laboratory (DDL) is one of the world’s leading vaccine research and development labs. It was founded in 2008 with a focus on HIV vaccines, and that work continues. In addition, the DDL is also IAVI’s vaccine development hub for emerging infectious diseases (EIDs).
DDL principal investigators
- Christopher Parks, associate vice president, viral vaccines; head of the DDL
- Christopher Cooper, director, viral vaccines, DDL
- Gavin Morrow, associate director of vector immunobiology, DDL
- Thomas Postler, principal scientist, DDL
- Suzane Ramos da Silva, principal scientist, DDL
We harness promising vector technology for EID vaccine development
The DDL develops EID vaccines that are based on the vesicular stomatitis virus (VSV) vector. DDL scientists specialize in the same VSV vector that is used in ERVEBO®, Merck’s single-dose Ebola Zaire virus vaccine, which has been used extensively in adults and children. Hundreds of thousands of people in West Africa have received this safe, effective vaccine, which is now licensed in more than a dozen countries.
If proven effective, we’re hopeful that vaccine candidates built on VSV will be similarly important for future EID outbreak responses. Watch our video below on how VSV vaccines work.
EID pathogens we prioritize
Lassa virus
Causes: Lassa hemorrhagic fever
No vaccine available
More about what we do at the DDL
- Develop new viral vectors and immunogens
- Test vaccine concepts in vivo
- Develop laboratory tests to characterize vaccine candidates and the immune responses they induce
- Educate students and local communities about vaccine science
- Collaborate with other scientists
- Publish research in scientific journals
Learn more about EIDs
Our global network of collaborators & supporters
The DDL collaborates with investigators at the following institutions, among others:
Work at the DDL is supported by
- Coalition for Epidemic Preparedness Innovations
- Government of Japan
- U.S. Biomedical Advanced Research and Development Authority
- U.S. Defense Threat Reduction Agency
- U.S. National Institutes of Health (NIH)
- U.S. NIH National Institute of Allergy and Infectious Diseases
FEATURED ‘News of the Day’, as reported by public domain newswires.
View ALL Headlines & Breaking News here.
Source Information (if available)
This article originally appeared on www.iavi.org by IAVI – sharing via newswires in the public domain, repeatedly. News articles have become eerily similar to manufacturer descriptions.
We will happily entertain any content removal requests, simply reach out to us. In the interim, please perform due diligence and place any content you deem “privileged” behind a subscription and/or paywall.
CPT (CryptoPolyTech) PPP (Public Press Pass) Coverage features stories and headlines you may not otherwise see due to the manipulation of mass media.
First to share? If share image does not populate, please close the share box & re-open or reload page to load the image, Thanks!